In 2019,ACS Medicinal Chemistry Letters included an article by Harrison, Tyler J.; Bauer, Daniel; Berdichevsky, Alina; Chen, Xin; Duvadie, Rohit; Hoogheem, Benjamin; Hatsis, Panos; Liu, Qian; Mao, Justin; Miduturu, Vasumathy; Rocheford, Erik; Zecri, Frederic; Zessis, Richard; Zheng, Rui; Zhu, Qingming; Streeper, Ryan; Patel, Sejal J.. Application of 13534-97-9. The article was titled 《Successful Strategies for Mitigation of a Preclinical Signal for Phototoxicity in a DGAT1 Inhibitor》. The information in the text is summarized as follows:
Diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor Pradigastat (1) was shown to be effective at decreasing postprandial triglyceride levels in a patient population with familial chylomicronemia syndrome (FCS). Although pradigastat does not cause photosensitization in humans at the high clin. dose of 40 mg, a pos. signal was observed in preclin. models of phototoxicity. Herein, we describe a preclin. phototoxicity mitigation strategy for diarylamine containing mols. utilizing the introduction of an amide or suitable heterocyclic function. This strategy led to the development of two second-generation compounds with low risk of phototoxicity, disparate exposure profiles, and comparable efficacy to 1 in a rodent lipid bolus model for post-prandial plasma triglycerides. After reading the article, we found that the author used 6-Bromopyridin-3-amine(cas: 13534-97-9Application of 13534-97-9)
6-Bromopyridin-3-amine(cas: 13534-97-9) belongs to anime. The reaction of alkyl halides, R―X, where X is a halogen, or analogous reagents with ammonia (or amines) is useful with certain compounds. Not all alkyl halides are effective reagents; the reaction is sluggish with secondary alkyl groups and fails with tertiary ones. Its usefulness is largely confined to primary alkyl halides (those having two hydrogen atoms on the reacting site).Application of 13534-97-9